This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vorwerk, P. Articles by Mittler, U. Search for Related Content PubMed PubMed Citation Articles by Vorwerk, P. Articles by Mittler, U.

Insulin-Like Growth Factor Binding Protein-2 at Diagnosis of Childhood Acute Lymphoblastic Leukemia and the Prediction of Relapse Risk

Department of Pediatric Hematology/Oncology (P.V., H.W., U.M.), Department of General Pediatrics (K.M.), Institute of Biometrics and Medical Informatics (F.-W.R.), University Otto von Guericke Magdeburg, D-39112 Magdeburg, Germany; Department of Pediatric Hematology/Oncology (M.Z.), Hannover Medical School, D-30625 Hannover, Germany; Eli Lilly and Company (W.F.B.), 61350 Bad Homburg, Germany; and University Children’s Hospital (W.F.B.), D-35385 Gießen, Germany

Address all correspondence and requests for reprints to: Dr. Peter Vorwerk, Department of Pediatric Hematology/Oncology, University Otto von Guericke, E.-Larisch-Weg 17-19, D-39112 Magdeburg, Germany. E-mail: Peter.Vorwerk{at}medizin.uni-magdeburg.de.

Despite remarkable advances in the clinical outcome of most children with acute lymphoblastic leukemia, a substantial number of patients ultimately relapse or suffer from side effects of treatment. In the present study, we investigated components of the IGF system for their predictive value to identify patients with an increased risk of relapse.

Serum levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, and IGFBP-3 were measured in 162 children with acute lymphoblastic leukemia treated by the Berlin Frankfurt Münster Study Group. At diagnosis we found elevated IGFBP-2, low IGFBP-3, low IGF-I, and low normal IGF-II, but normal IGFBP-1 levels. Highly elevated IGFBP-2 and low IGFBP-3 at the time of diagnosis correlated with a higher risk of an event such as lack of remission or a relapse. Serum IGFBP-2 was identified as an independent factor that adds additional information for the prediction of events (relapse or treatment failure) to the conventional prognostic factors such as white blood cell count and platelet count at diagnosis.

This article has been cited by other articles:

				B. Rikhof, J. van Doorn, A. J. H. Suurmeijer, M. W. Rautenberg, P. J. T. A. Groenen, M. A. J. Verdijk, P. L. Jager, S. de Jong, J. A. Gietema, and W. T. A. van der Graaf Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour Ann. Onc., March 10, 2009; (2009) mdp038v1. [Abstract] [Full Text] [PDF]

				S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang Insulin-like growth factor binding protein 2 promotes glioma development and progression PNAS, July 10, 2007; 104(28): 11736 - 11741. [Abstract] [Full Text] [PDF]

				R. Mehrian-Shai, C. D. Chen, T. Shi, S. Horvath, S. F. Nelson, J. K. V. Reichardt, and C. L. Sawyers Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer PNAS, March 27, 2007; 104(13): 5563 - 5568. [Abstract] [Full Text] [PDF]